$LQDA

Bloch Stephen M sold $14.0M of LQDA (indirect holdings)

Bloch Stephen M sold 196,111 indirectly-held shares of Liquidia Corp (LQDA) at an average of $71.45 ($71.37–$72.15, $14.01M total) across 4 trades over 2026-06-12 to 2026-06-15.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 16, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The newest information is the disclosed $14.0M open-market sale (196,111 shares) and the director’s post-transaction holdings (980,073 shares), with no 10b5-1 plan cited.

02

Market read

Traders may react to the disclosed insider selling size and the absence of a 10b5-1 plan, but there is no accompanying operational or financial update.

03

What to watch

The filing states the sales were not under a pre-arranged 10b5-1 plan, but it does not disclose the director’s broader compensation/financial needs or whether other holdings were adjusted concurrently.

Relevance 7/10Novelty 8/10Timing: Filed 2026-06-16; sale executed 2026-06-12 to 2026-06-15.

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Stephen M. Bloch sold $14.0M of LQDA shares via open-market transactions (Form 4) during 2026-06-12 to 2026-06-15.

Expected impact

Near-term: slight bearish bias; magnitude likely limited because it’s a disclosed Form 4 without new fundamentals.

Evidence & confidence

The article provides a concrete sale size, timing, and role (director) plus absence of a pre-arranged 10b5-1 plan, which traders may interpret as higher signaling risk.

Market effects

Limited sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity management and may not reflect company outlook, especially when multiple small trades are spread across days.

Key entities

  • Liquidia Corp

    US-listed company whose director insider sale is disclosed on Form 4.

  • Stephen M. Bloch

    Director reporting the open-market sale of LQDA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient